Trials / Terminated
TerminatedNCT01092546
Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
A Principal, Prospective, Open-label Biopsy Study to Validate Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Normal Pressure Hydrocephalus (NPH) Subjects.
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]Flutemetamol | All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq. |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2010-03-25
- Last updated
- 2013-12-13
- Results posted
- 2013-11-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01092546. Inclusion in this directory is not an endorsement.